Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 2/20 | 0.39 |
| ▸ | GABRD | O14764 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.39 |
| ▸ | GABRE | P78334 | 2/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1813910 | 1.00 | ALDH1A1 (0.43) | ALDH1A1METAP1GABRPGABRDGABRA1 | |
| SCHEMBL2436666 | 1.00 | ALDH1A1 (0.43) | ALDH1A1METAP1GABRPGABRDGABRA1 | |
| SCHEMBL6061612 | 1.00 | ALDH1A1 (0.43) | ALDH1A1METAP1GABRPGABRDGABRA1 | |
| SCHEMBL6061124 | 1.00 | ALDH1A1 (0.43) | ALDH1A1METAP1GABRPGABRDGABRA1 | |
| SCHEMBL14892833 | 1.00 | ALDH1A1 (0.43) | ALDH1A1METAP1GABRPGABRDGABRA1 | |
| Hydrochloric Acid SCHEMBL4448412 | 0.98 | ALDH1A1 (0.42) | ALDH1A1METAP1GABRPGABRDGABRA1 | |
| Hydrochloric Acid SCHEMBL6067671 | 0.98 | ALDH1A1 (0.42) | ALDH1A1METAP1GABRPGABRDGABRA1 | |
| SCHEMBL6061959 | 0.89 | GPR84 (0.43) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL4929759 | 0.89 | GPR84 (0.43) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL6061174 | 0.89 | GPR84 (0.43) | ALDH1A1GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 752 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACETICALS LTD (NZ) | 2025-07-08 | — | — | US | claimed |
| US-20220347104-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | DOUGLAS PHARMACEUTICALS LTD. (NZ) | 2022-11-03 | — | — | US | claimed |
| US-11471416-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2022-10-18 | — | — | US | claimed |
| US-20200323795-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | UNIVERSITY OF OTAGO (NZ) | 2020-10-15 | — | — | US | claimed |
| CN-111630026-A | Sustained release pharmaceutical formulations and methods of treatment | 道格拉斯制药有限公司 | 2020-09-04 | — | — | CN | claimed |
| EP-3694832-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | Douglas Pharmaceuticals Limited (NZ) | 2020-08-19 | — | — | EP | claimed |
| US-10744094-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2020-08-18 | — | — | US | claimed |
| US-20190224127-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2019-07-25 | — | — | US | claimed |
| WO-2019073408-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | DOUGLAS PHARMACEUTICALS LTD. (NZ) | 2019-04-18 | — | — | WO | claimed |
| US-20190105276-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2019-04-11 | — | — | US | claimed |
| EP-2175728-B1 | SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2014-09-10 | — | — | EP | claimed |
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-05-26 | — | — | US | claimed |
| US-20070191350-A1 | Combinations comprising alpha-2-delta ligands | PIFIZER INC. (US) | 2007-08-16 | — | — | US | claimed |
| EP-1727535-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | Pfizer Limited (GB) | 2006-12-06 | — | — | EP | claimed |
| EP-1667957-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005102390-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND NMDA RECEPTOR ANTAGONISTS | PFIZER JAPAN, INC. (JP) | 2005-11-03 | — | — | WO | claimed |
| WO-2005092318-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | claimed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | claimed |
| WO-2005030700-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | claimed |
| US-20260146036-A1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC. (JP) | 2026-05-28 | — | — | US | disclosed |
| EP-4377309-B1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC (JP) | 2026-05-20 | — | — | EP | disclosed |
| US-12611386-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS LTD. (NZ) | 2026-04-28 | — | — | US | disclosed |
| EP-4714435-A2 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | Vertex Pharmaceuticals Incorporated (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4712957-A2 | ISOANDROGRAPHOLIDE ANALOGS AND METHOD FOR TREATMENT USING THE SAME | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4712967-A2 | G-PROTEIN COUPLED RECEPTOR ANTAGONIST | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4699607-A2 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12552776-B2 | Crystalline forms | RAQUALIA PHARMA INC. (JP) | 2026-02-17 | — | — | US | disclosed |
| US-20260034065-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2026-02-05 | — | — | US | disclosed |
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-01 | — | — | US | disclosed |
| US-20260001861-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4346818-B1 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | VERTEX PHARMA (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250353836-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2025-11-20 | — | — | US | disclosed |
| US-12472146-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2025-11-18 | — | — | US | disclosed |
| EP-4347031-B1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4629968-A1 | NOOTKATONE FOR THE TREATMENT OF PRURITUS | Enveda Therapeutics, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4629974-A1 | NOOTKATONE FOR THE TREATMENT OF GUT OR ABDOMINAL PAIN | Enveda Therapeutics, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-3820860-B1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-12441703-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-10-14 | — | — | US | disclosed |
| US-12440481-B2 | Esters and carbamates as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-10-14 | — | — | US | disclosed |
| US-12421191-B2 | 3-hydroxyoxindole derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2025-09-23 | — | — | US | disclosed |
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACETICALS LTD (NZ) | 2025-07-08 | — | — | US | disclosed |
| US-12350378-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACETICALS LTD (NZ) | 2025-07-08 | — | — | US | disclosed |
| US-20250213555-A1 | SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250197381-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-19 | — | — | US | disclosed |
| WO-2025122953-A1 | DOSING REGIMENS AND FORMULATIONS OF SUZETRIGINE FOR USE IN THE TREATMENT OF ACUTE AND CHRONIC PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250186419-A1 | DOSING REGIMENS FOR TREATING PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2025090465-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025090516-A1 | METHODS OF PREPARING COMPOUNDS FOR TREATING PAIN AND SOLID FORMS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025090480-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025090511-A1 | METHODS OF PREPARING MODULATORS OF SODIUM CHANNELS AND SOLID FORMS OF THE SAME FOR TREATING PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-01 | — | — | WO | disclosed |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-22 | — | — | US | disclosed |
| US-12258333-B2 | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-03-25 | — | — | US | disclosed |
| CN-119677737-A | Heteroaryl compounds for the treatment of pain | 沃泰克斯药物股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-12247021-B2 | Substituted tetrahydrofurans as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-03-11 | — | — | US | disclosed |
| CN-119546580-A | Heteroaryl compounds for the treatment of pain | 沃泰克斯药物股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4511117-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-4511114-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-4511116-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-4511115-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12234221-B2 | Pyridine carboxamide compounds for inhibiting NAV1.8 | LIEBER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20250049734-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD. (NZ) | 2025-02-13 | — | — | US | disclosed |
| EP-4506001-A2 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-112689633-B | For inhibiting Nav1.8 Pyridinecarboxamide Compounds | 利伯研究所公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-3946296-B9 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-12-25 | — | — | EP | disclosed |
| US-20240400544-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDE ANALOGS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240391907-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-11-28 | — | — | US | disclosed |
| WO-2024239000-A2 | G-PROTEIN COUPLED RECEPTOR ANTAGONIST | ENVEDA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-3651752-B1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-114945566-B | Substituted tetrahydrofurans as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-12128140-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2024-10-29 | — | — | US | disclosed |
| US-20240351998-A1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC. (JP) | 2024-10-24 | — | — | US | disclosed |
| US-20240336574-A1 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. | 2024-10-10 | — | — | US | disclosed |
| US-12110287-B2 | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2024-10-08 | — | — | US | disclosed |
| EP-4069691-B1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2024-09-18 | — | — | EP | disclosed |
| US-12090123-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS LTD. (NZ) | 2024-09-17 | — | — | US | disclosed |
| US-20240294512-A1 | HYDROXY AND (HALO)ALKOXY SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-09-05 | — | — | US | disclosed |
| US-20240285596-A1 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-08-29 | — | — | US | disclosed |
| EP-3617195-B1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVES AS INHIBITORS OF TROPOMYOSIN RECEPTOR KINASE A FOR THE TREATMENT OF PAIN | MOCHIDA PHARM CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| EP-3459958-B1 | PROCESS AND INTERMEDIATES FOR PREPARING PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20240238328-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | GLYCOLOGIX INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240189259-A2 | Extended Release Pharmaceutical Formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2024-06-13 | — | — | US | disclosed |
| WO-2024123826-A1 | NOOTKATONE FOR IMPROVING THE APPEARANCE OF SKIN | ENVEDA THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123830-A1 | NOOTKATONE FOR THE TREATMENT OF GUT OR ABDOMINAL PAIN | ENVEDA THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123824-A1 | NOOTKATONE FOR THE TREATMENT OF PRURITUS | ENVEDA THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123825-A1 | NOOTKATONE FOR THE TREATMENT OF PSORIASIS OR ATOPIC DERMATITIS | ENVEDA THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123828-A1 | NOOTKATONE FOR THE TREATMENT OF DIABETIC DERMOPATHY OR DIABETIC PERIPHERAL NEUROPATHY | ENVEDA THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20240182455-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2024-06-06 | — | — | US | disclosed |
| EP-4377309-A1 | CRYSTALLINE FORMS | RaQualia Pharma Inc. (JP) | 2024-06-05 | — | — | EP | disclosed |
| US-11993581-B2 | Pyridazine compounds for inhibiting Nav1.8 | LIEBER INSTITUE, INC (US) | 2024-05-28 | — | — | US | disclosed |
| US-11975019-B2 | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | GLYCOLOGIX, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| EP-3946296-B1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-05-01 | — | — | EP | disclosed |
| CN-112689629-B | For inhibiting Nav1.8 Pyridazine Compounds | 利伯研究所公司 | 2024-04-23 | — | — | CN | disclosed |
| EP-4347583-A1 | SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347032-A1 | SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4346818-A1 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | Vertex Pharmaceuticals Incorporated (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347031-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347584-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDE ANALOGS AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347033-A1 | HYDROXY AND (HALO)ALKOXY SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117858875-A | Hydroxy-and (halo) alkoxy-substituted tetrahydrofurans as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117813302-A | Substituted tetrahydrofuran-2-carboxamides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117794920-A | N- (hydroxyalkyl (hetero) aryl) tetrahydrofurancarboxamides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117794918-A | Substituted tetrahydrofuran analogues as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117794537-A | Solid dosage forms and dosing regimens comprising (2 r,3s,4s,5 r) -4- [ [3- (3, 4-difluoro-2-methoxy-phenyl) -4, 5-dimethyl-5- (trifluoromethyl) tetrahydrofuran-2-carbonyl ] amino ] pyridine-2-carboxamide | 沃泰克斯药物股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117794919-A | N- (hydroxyalkyl (hetero) aryl) tetrahydrofurancarboxamide analogues as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11919887-B2 | Substituted tetrahydrofurans as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-03-05 | — | — | US | disclosed |
| CN-117616022-A | Crystalline forms | 拉夸里亚创药株式会社 | 2024-02-27 | — | — | CN | disclosed |
| US-11911411-B2 | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | GLYCOLOGIX, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240018103-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-4304585-A2 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | Latigo Biotherapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11834441-B2 | Substituted tetrahydrofurans as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-11827627-B2 | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-23 | — | — | US | disclosed |
| CN-110831926-B | Tetrahydronaphtyl urea derivatives | 持田制药株式会社 | 2023-11-21 | — | — | CN | disclosed |
| CN-117062607-A | Methyl substituted pyridine and pyridazine compounds, derivatives thereof and methods of use thereof | 拉堤果生物医疗股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230355548-A1 | Extended Release Pharmaceutical Formulation | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2023-11-09 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| WO-2023205465-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205778-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205463-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205468-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| CN-111868037-B | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2023-10-13 | — | — | CN | disclosed |
| US-11773119-B2 | Prodrugs of pyridone amides useful as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286961-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2023-09-14 | — | — | US | disclosed |
| CN-110740993-B | Deuterated pyridonamides and prodrugs thereof useful as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-4222142-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | RaQualia Pharma Inc. (JP) | 2023-08-09 | — | — | EP | disclosed |
| EP-4216937-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | Douglas Pharmaceuticals Limited (NZ) | 2023-08-02 | — | — | EP | disclosed |
| CN-116456972-A | Prolonged release pharmaceutical formulations | 道格拉斯制药有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-11673864-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| CN-110612285-B | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2023-04-04 | — | — | CN | disclosed |
| US-11603351-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-03-14 | — | — | US | disclosed |
| US-20230062053-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2023-03-02 | — | — | US | disclosed |
| CN-115697352-A | Sulfated glycosaminoglycan biomaterials as proteoglycan mimetics | 格莱克罗吉克斯公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2023008585-A1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC. (JP) | 2023-02-02 | — | — | WO | disclosed |
| EP-4121064-A1 | SULFATED GLYCOSAMINOGLYCAN BIOMATERIALS AS PROTEOGLYCAN MIMICS | Glycologix, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-20230009251-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| US-20220387355-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2022-12-08 | — | — | US | disclosed |
| WO-2022256622-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022256842-A1 | HYDROXY AND (HALO)ALKOXY SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022256679-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDE ANALOGS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022256676-A1 | SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022256708-A1 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022256702-A1 | SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20220354798-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2022-11-10 | — | — | US | disclosed |
| US-20220347104-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | DOUGLAS PHARMACEUTICALS LTD. (NZ) | 2022-11-03 | — | — | US | disclosed |
| US-11471416-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2022-10-18 | — | — | US | disclosed |
| US-11471415-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2022-10-18 | — | — | US | disclosed |
| EP-4069691-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2022-10-12 | — | — | EP | disclosed |
| WO-2022192487-A2 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-114945566-A | Substituted tetrahydrofurans as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220227732-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2022-07-21 | — | — | US | disclosed |
| EP-3625214-B1 | DEUTERATED PYRIDONE AMIDES AND PRODRUGS THEREOF AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20220183983-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2022-06-16 | — | — | US | disclosed |
| US-11358977-B2 | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20220110923-A1 | ESTERS AND CARBAMATES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2022-04-14 | — | — | US | disclosed |
| WO-2022071484-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2022-04-07 | — | — | WO | disclosed |
| WO-2022064387-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD. (NZ) | 2022-03-31 | — | — | WO | disclosed |
| US-20220048892-A1 | HETEROCYCLIC DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2022-02-17 | — | — | US | disclosed |
| EP-3946296-A2 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | Douglas Pharmaceuticals Limited (NZ) | 2022-02-09 | — | — | EP | disclosed |
| CN-113939286-A | Sustained release pharmaceutical formulation | 道格拉斯制药有限公司 | 2022-01-14 | — | — | CN | disclosed |
| US-20220000905-A1 | SULFATED GLYCOSAMINOGLYCAN BIOMATERIALS AS PROTEOGLYCAN MIMICS | GLYCOLOGIX, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11203571-B2 | Sulfonamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3902544-A1 | HETEROCYCLIC DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RaQualia Pharma Inc. (JP) | 2021-11-03 | — | — | EP | disclosed |
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2021-10-26 | — | — | US | disclosed |
| US-20210290657-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | GLYCOLOGIX, LLC | 2021-09-23 | — | — | US | disclosed |
| WO-2021188882-A1 | SULFATED GLYCOSAMINOGLYCAN BIOMATERIALS AS PROTEOGLYCAN MIMICS | GLYCOLOGIX, LLC (US) | 2021-09-23 | — | — | WO | disclosed |
| EP-3865475-A1 | PROCESS FOR PREPARING PYRIDONE AMIDES WHICH ARE MODULATORS OF SODIUM CHANNELS AND INTERMEDIATE COMPOUNDS USED THEREIN | Vertex Pharmaceuticals Incorporated (US) | 2021-08-18 | — | — | EP | disclosed |
| US-11090327-B2 | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | GLYCOLOGIX, LLC (US) | 2021-08-17 | — | — | US | disclosed |
| CN-106459147-B | Serine derivatives as ghrelin receptor agonists | 拉夸里亚创药株式会社 | 2021-08-06 | — | — | CN | disclosed |
| CN-108395452-B | Prodrugs of pyridone amides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2021-08-03 | — | — | CN | disclosed |
| CN-113164461-A | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2021-07-23 | — | — | CN | disclosed |
| WO-2021145401-A1 | SPIROHETEROCYCLIC DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-07-22 | — | — | WO | disclosed |
| CN-108164457-B | Pyridone amides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-108658964-B | Polymorphic substance | 拉夸里亚创药株式会社 | 2021-07-02 | — | — | CN | disclosed |
| US-20210198241-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-07-01 | — | — | US | disclosed |
| US-11045424-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS LTD. (NZ) | 2021-06-29 | — | — | US | disclosed |
| WO-2021113627-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-10 | — | — | WO | disclosed |
| US-11020381-B2 | Biaryloxy derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2021-06-01 | — | — | US | disclosed |
| US-20210155643-A1 | DEUTERATED PYRIDONE AMIDES AND PRODRUGS THEREOF AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-05-27 | — | — | US | disclosed |
| EP-3820866-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | Lieber Institute, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-3820860-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | Lieber Institute, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | disclosed |
| CN-112689633-A | For inhibiting Nav1.8 pyridine carboxamide Compounds | 利伯研究所公司 | 2021-04-20 | — | — | CN | disclosed |
| CN-112689629-A | For inhibiting Nav1.8 pyridazine Compounds | 利伯研究所公司 | 2021-04-20 | — | — | CN | disclosed |
| US-20210094906-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-04-01 | — | — | US | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| CN-106103416-B | Azaspiro derivatives as TRPM8 antagonists | 拉夸里亚创药株式会社 | 2021-03-02 | — | — | CN | disclosed |
| US-20210052517-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2021-02-25 | — | — | US | disclosed |
| US-10927079-B2 | Intermediate compound of novel tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-23 | — | — | US | disclosed |
| US-20210047271-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2021-02-18 | — | — | US | disclosed |
| EP-3774739-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RaQualia Pharma Inc. (JP) | 2021-02-17 | — | — | EP | disclosed |
| EP-3487839-B1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC (JP) | 2020-12-23 | — | — | EP | disclosed |
| EP-3239134-B1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10869838-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2020-12-22 | — | — | US | disclosed |
| US-20200377535-A1 | PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-12-03 | — | — | US | disclosed |
| EP-3116858-B1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2020-11-11 | — | — | EP | disclosed |
| CN-111868037-A | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2020-10-30 | — | — | CN | disclosed |
| WO-2020219867-A1 | PYRIDONE AMIDE CO-CRYSTAL COMPOSITIONS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-10-29 | — | — | WO | disclosed |
| US-20200323795-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | UNIVERSITY OF OTAGO (NZ) | 2020-10-15 | — | — | US | disclosed |
| WO-2020194087-A2 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD. (NZ) | 2020-10-01 | — | — | WO | disclosed |
| US-20200306194-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | UNIVERSITY OF OTAGO (NZ) | 2020-10-01 | — | — | US | disclosed |
| US-10787472-B2 | Prodrugs of pyridone amides useful as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-29 | — | — | US | disclosed |
| CN-111630026-A | Sustained release pharmaceutical formulations and methods of treatment | 道格拉斯制药有限公司 | 2020-09-04 | — | — | CN | disclosed |
| EP-3694832-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | Douglas Pharmaceuticals Limited (NZ) | 2020-08-19 | — | — | EP | disclosed |
| US-10744094-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2020-08-18 | — | — | US | disclosed |
| US-10738009-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-08-11 | — | — | US | disclosed |
| CN-107074837-B | Benzisoxazole derivative salts | 拉夸里亚创药株式会社 | 2020-07-28 | — | — | CN | disclosed |
| US-20200230123-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2020-07-23 | — | — | US | disclosed |
| WO-2020146682-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020146612-A1 | ESTERS AND CARBAMATES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020138271-A1 | HETEROCYCLIC DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2020-07-02 | — | — | WO | disclosed |
| US-10669239-B2 | Tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-02 | — | — | US | disclosed |
| EP-3651752-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2020-05-20 | — | — | EP | disclosed |
| US-10647661-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-12 | — | — | US | disclosed |
| CN-111065383-A | Carboxamides useful as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2020-04-24 | — | — | CN | disclosed |
| EP-3632899-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RaQualia Pharma Inc. (JP) | 2020-04-08 | — | — | EP | disclosed |
| EP-3625214-A1 | DEUTERATED PYRIDONE AMIDES AND PRODRUGS THEREOF AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3617195-A1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVES | Mochida Pharmaceutical Co., Ltd. (JP) | 2020-03-04 | — | — | EP | disclosed |
| EP-2435407-B1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2019-12-25 | — | — | EP | disclosed |
| CN-110612285-A | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2019-12-24 | — | — | CN | disclosed |
| CN-106220572-B | Pyridazine derivative compound, application, composition and kit and preparation method | 因西必泰克新有限公司 | 2019-12-13 | — | — | CN | disclosed |
| US-20190337897-A1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2019-11-07 | — | — | US | disclosed |
| WO-2019198692-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2019-10-17 | — | — | WO | disclosed |
| US-10441544-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2019-10-15 | — | — | US | disclosed |
| US-20190276483-A1 | PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2019-09-12 | — | — | US | disclosed |
| US-10399945-B2 | Tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2019-09-03 | — | — | US | disclosed |
| US-20190262386-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | GLYCOLOGIX, INC. | 2019-08-29 | — | — | US | disclosed |
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190248745-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2019-08-15 | — | — | US | disclosed |
| US-20190224127-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2019-07-25 | — | — | US | disclosed |
| EP-3512561-A1 | SULFATED GLYCOSAMINOGLYCAN BIOMATERIALS AS PROTEOGLYCAN MIMICS | Glycologix, LLC (US) | 2019-07-24 | — | — | EP | disclosed |
| US-20190216740-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | UNIVERSITY OF OTAGO (NZ) | 2019-07-18 | — | — | US | disclosed |
| EP-3243815-B1 | PYRIDAZINE DERIVATIVES USEFUL IN THERAPY | INHIBITAXIN LTD (GB) | 2019-07-10 | — | — | EP | disclosed |
| EP-3145926-B1 | BENZISOXAZOLE DERIVATIVE SALT | RAQUALIA PHARMA INC (JP) | 2019-07-03 | — | — | EP | disclosed |
| EP-2951155-B1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-2841421-B1 | AMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2019-06-05 | — | — | EP | disclosed |
| EP-3487839-A1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RaQualia Pharma Inc. (JP) | 2019-05-29 | — | — | EP | disclosed |
| WO-2019073408-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | DOUGLAS PHARMACEUTICALS LTD. (NZ) | 2019-04-18 | — | — | WO | disclosed |
| US-20190105276-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2019-04-11 | — | — | US | disclosed |
| US-10253054-B2 | Prodrugs of pyridone amides useful as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-04-09 | — | — | US | disclosed |
| EP-3459958-A1 | PROCESS AND INTERMEDIATES FOR PREPARING PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-03-19 | — | — | US | disclosed |
| US-20190023657-A1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2019-01-24 | — | — | US | disclosed |
| US-20190016671-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| WO-2019014352-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-17 | — | — | WO | disclosed |
| US-10179779-B2 | Polymorph forms | RAQUALIA PHARMA INC. (JP) | 2019-01-15 | — | — | US | disclosed |
| WO-2018235851-A1 | AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2018-12-27 | — | — | WO | disclosed |
| US-20180339993-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2018-11-29 | — | — | US | disclosed |
| WO-2018213426-A1 | DEUTERATED PYRIDONE AMIDES AND PRODRUGS THEREOF AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-11-22 | — | — | WO | disclosed |
| EP-3131916-B1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC (JP) | 2018-11-14 | — | — | EP | disclosed |
| US-20180305341-A1 | IMIDAZOLINONE DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2018-10-25 | — | — | US | disclosed |
| US-10093678-B2 | Azaspiro derivatives as TRPM8 antagonists | RAQUALIA PHARMA INC. (JP) | 2018-10-09 | — | — | US | disclosed |
| US-10087143-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-10-02 | — | — | US | disclosed |
| EP-2938607-B1 | SALTS AND CRYSTAL FORMS OF A COX-2 INHIBITOR | ASKAT INC (JP) | 2018-09-12 | — | — | EP | disclosed |
| EP-3080134-B1 | PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3350171-A1 | IMIDAZOLINONE DERIVATIVES AS TRPM8 ANTAGONISTS | RaQualia Pharma Inc. (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-10016420-B2 | Substituted pyridazines for the treatment of pain | INHIBITAXIN LIMITED (GB) | 2018-07-10 | — | — | US | disclosed |
| EP-3004100-B1 | POLYMORPH FORMS | RAQUALIA PHARMA INC (JP) | 2018-06-27 | — | — | EP | disclosed |
| US-9988370-B2 | Benzisoxazole derivative salt | RAQUALIA PHARMA INC. (JP) | 2018-06-05 | — | — | US | disclosed |
| EP-3321283-A1 | TREATMENT OF CHRONIC PROSTATITIS | Pfizer Inc (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9944634-B2 | Pyrazolopyridine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2018-04-17 | — | — | US | disclosed |
| WO-2018053276-A1 | SULFATED GLYCOSAMINOGLYCAN BIOMATERIALS AS PROTEOGLYCAN MIMICS | GLYCOLOGIX, LLC (US) | 2018-03-22 | — | — | WO | disclosed |
| US-9901571-B2 | Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists | RAQUALIA PHARMA INC. (JP) | 2018-02-27 | — | — | US | disclosed |
| US-20180044361-A1 | PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-02-15 | — | — | US | disclosed |
| US-9873695-B2 | Serine derivatives as ghrelin receptor agonists | RAQUALIA PHARMA INC. (JP) | 2018-01-23 | — | — | US | disclosed |
| US-20180016235-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-01-18 | — | — | US | disclosed |
| EP-2914597-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2017-12-06 | — | — | EP | disclosed |
| US-9828397-B2 | Prodrugs of pyridone amides useful as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-11-28 | — | — | US | disclosed |
| EP-3243815-A1 | PYRIDAZINE DERIVATIVES USEFUL IN THERAPY | Inhibitaxin Limited (GB) | 2017-11-15 | — | — | EP | disclosed |
| EP-2291403-B1 | TREATMENT OF CHRONIC PROSTATITIS | PFIZER (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-3022175-B1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3239134-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170304277-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-10-26 | — | — | US | disclosed |
| US-9783501-B2 | Substituted quinolines as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-10 | — | — | US | disclosed |
| US-9758483-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-12 | — | — | US | disclosed |
| EP-3212648-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RaQualia Pharma Inc. (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-2841435-B1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-2675812-B1 | CHROMAN - SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170197961-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-07-13 | — | — | US | disclosed |
| EP-2922849-B1 | POLYMORPHS OF 4-{[4-({[4-(2,2,2-TRIFLUOROETHOXY)-1,2-BENZISOXAZOL-3-YL]OXY}METHYL)PIPERIDIN-1-YL]METHYL}-TETRAHYDRO-2H-PYRAN-4-CARBOXYLIC ACID AS 5-HYDROXYTRYPTAMINE-4 (5-HT4) RECEPTOR AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | RAQUALIA PHARMA INC (JP) | 2017-07-12 | — | — | EP | disclosed |
| US-9701658-B2 | Amide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2017-07-11 | — | — | US | disclosed |
| EP-2771325-B1 | PYRIDAZINE DERIVATIVES USEFUL IN THERAPY | INHIBITAXIN LTD (GB) | 2017-06-28 | — | — | EP | disclosed |
| US-20170145011-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMA (US) | 2017-05-25 | — | — | US | disclosed |
| EP-2804868-B1 | PYRAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-3145926-A1 | BENZISOXAZOLE DERIVATIVE SALT | RaQualia Pharma Inc (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20170081318-A1 | BENZISOXAZOLE DERIVATIVE SALT | RAQUALIA PHARMA INC. (JP) | 2017-03-23 | — | — | US | disclosed |
| WO-2017043092-A1 | IMIDAZOLINONE DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-03-16 | — | — | WO | disclosed |
| EP-2710002-B1 | POLYMORPH FORM OF 4-{[4-({[4-(2,2,2-TRIFLUOROETHOXY)-1,2-BENZISOXAZOL-3-YL]OXY}METHYL)PIPERIDIN-1-YL]METHYL}-TETRAHYDRO-2H-PYRAN-4-CARBOXYLIC ACID | RAQUALIA PHARMA INC (JP) | 2017-03-01 | — | — | EP | disclosed |
| EP-2953931-B1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-3131916-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RaQualia Pharma Inc (JP) | 2017-02-22 | — | — | EP | disclosed |
| US-20170037009-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2017-02-09 | — | — | US | disclosed |
| EP-3116858-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RaQualia Pharma Inc. (JP) | 2017-01-18 | — | — | EP | disclosed |
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
| EP-2951168-B1 | QUINOLINE AND QUINOXALINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20160376295-A1 | PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-29 | — | — | US | disclosed |
| US-9522140-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2016-12-20 | — | — | US | disclosed |
| EP-2686325-B1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-12-14 | — | — | EP | disclosed |
| US-9511067-B2 | Substituted spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]s as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-06 | — | — | US | disclosed |
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-9499543-B2 | Polymorph forms | RAQUALIA PHARMA INC. (JP) | 2016-11-22 | — | — | US | disclosed |
| EP-3080134-A1 | PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9464102-B2 | Prodrugs of pyridone amides useful as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160287584-A1 | SUBSTITUTED PYRIDAZINES FOR THE TREATMENT OF PAIN | INHIBITAXIN LTD (GB) | 2016-10-06 | — | — | US | disclosed |
| US-9447096-B2 | — | — | 2016-09-20 | — | — | US | disclosed |
| US-9447066-B2 | Salts and crystal forms | ASKAT INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-9421196-B2 | Amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-23 | — | — | US | disclosed |
| EP-3056495-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Inc. (US) | 2016-08-17 | — | — | EP | disclosed |
| US-9403839-B2 | Pyran-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-02 | — | — | US | disclosed |
| EP-2791108-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2016-07-27 | — | — | EP | disclosed |
| US-9393235-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2595989-B1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-07-13 | — | — | EP | disclosed |
| US-9365588-B2 | Benzoxazines as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
| US-20160152561-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2016-06-02 | — | — | US | disclosed |
| EP-3022175-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Inc. (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-2694509-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN-RELATED KINASES | PFIZER LTD (GB) | 2016-05-18 | — | — | EP | disclosed |
| EP-3019478-A1 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2016067638-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2016-05-06 | — | — | WO | disclosed |
| EP-3004100-A1 | POLYMORPH FORMS | RaQualia Pharma Inc. (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20160083381-A1 | POLYMORPH FORMS | RAQUALIA PHARMA INC. (JP) | 2016-03-24 | — | — | US | disclosed |
| EP-2670752-B1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-03-16 | — | — | EP | disclosed |
| US-9273011-B2 | Substituted pyridazines for the treatment of pain | INHIBITAXIN LIMITED | 2016-03-01 | — | — | US | disclosed |
| WO-2016021191-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2016-02-11 | — | — | WO | disclosed |
| EP-2731959-B1 | ENKEPHALIN ANALOGUES | PFIZER LTD (GB) | 2016-02-03 | — | — | EP | disclosed |
| US-20160009743-A1 | PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2016-01-14 | — | — | US | disclosed |
| EP-2953931-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2015-12-16 | — | — | EP | disclosed |
| US-20150353520-A1 | SALTS AND CRYSTAL FORMS | ASKAT INC. (JP) | 2015-12-10 | — | — | US | disclosed |
| EP-2951155-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| EP-2951168-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| US-20150336945-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-26 | — | — | US | disclosed |
| WO-2015178020-A1 | BENZISOXAZOLE DERIVATIVE SALT | RAQUALIA PHARMA INC. (JP) | 2015-11-26 | — | — | WO | disclosed |
| US-20150328196-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-19 | — | — | US | disclosed |
| US-9187463-B2 | Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid | RAQUALIA PHARMA INC. (JP) | 2015-11-17 | — | — | US | disclosed |
| US-9187475-B2 | Pyrrolopyridinone derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150322055-A1 | POLYMORPH FORMS | RAQUALIA PHARMA INC. (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2015-11-12 | — | — | US | disclosed |
| US-9181273-B2 | Morpholine-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-10 | — | — | US | disclosed |
| EP-2938607-A1 | SALTS AND CRYSTAL FORMS | AskAt Inc. (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-9163042-B2 | Prodrugs of pyridone amides useful as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163021-B2 | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors | PFIZER LIMITED (GB) | 2015-10-20 | — | — | US | disclosed |
| US-20150291582-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20150291514-A1 | N-Aminosulfonyl Benzamides | PFIZER LIMTED (GB) | 2015-10-15 | — | — | US | disclosed |
| EP-2922849-A1 | POLYMORPH FORMS | RaQualia Pharma Inc (JP) | 2015-09-30 | — | — | EP | disclosed |
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-9139529-B2 | Substituted quinoxalines as sodium channel modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | disclosed |
| WO-2015136947-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2015-09-17 | — | — | WO | disclosed |
| US-20150250785-A1 | Tropomyosin-Related Kinase Inhibitors | PFIZER LIMITED (GB) | 2015-09-10 | — | — | US | disclosed |
| EP-2914597-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2015-09-09 | — | — | EP | disclosed |
| US-20150246912-A1 | Pyrrolo[3,2-C]Pyridine Tropomyosin-Related Kinase Inhibitors | PFIZER LIMITED (GB) | 2015-09-03 | — | — | US | disclosed |
| US-20150246028-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-09-03 | — | — | US | disclosed |
| EP-2912036-A1 | PYRROLO[3,2-C]PYRIDINE TROPOMYOSIN-RELATED KINASE INHIBITORS | Pfizer Limited (GB) | 2015-09-02 | — | — | EP | disclosed |
| US-9108903-B2 | Amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2809655-B1 | BENZIIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2903989-A1 | PYRROLO[2,3-D]PYRIMIDINE TROPOMYOSIN-RELATED KINASE INHIBITORS | Pfizer Limited (GB) | 2015-08-12 | — | — | EP | disclosed |
| EP-2903986-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | Pfizer Limited (GB) | 2015-08-12 | — | — | EP | disclosed |
| US-9101616-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2015-08-11 | — | — | US | disclosed |
| US-9102621-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-20150218172-A1 | Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors | PFIZER LIMITED (GB) | 2015-08-06 | — | — | US | disclosed |
| US-9096500-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-9096558-B2 | N-sulfonylbenzamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-9085517-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2015-07-21 | — | — | US | disclosed |
| US-9079878-B2 | (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators | PFIZER LIMITED (GB) | 2015-07-14 | — | — | US | disclosed |
| WO-2014120820-A9 | AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-07-02 | — | — | WO | disclosed |
| WO-2014120815-A9 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150174127-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-06-25 | — | — | US | disclosed |
| WO-2015089361-A1 | PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20150166589-A1 | PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2015-06-18 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051270-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2015006280-A9 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-14 | — | — | WO | disclosed |
| US-20150105393-A1 | AMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8999974-B2 | Acyl piperazine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20150094306-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2015-04-02 | — | — | US | disclosed |
| EP-2841435-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2015-03-04 | — | — | EP | disclosed |
| EP-2385938-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2015-03-04 | — | — | EP | disclosed |
| EP-2841421-A1 | AMIDE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-8969383-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8957025-B2 | Enkephalin analogues | PFIZER INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20150025073-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-01-22 | — | — | US | disclosed |
| WO-2015010065-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-22 | — | — | WO | disclosed |
| EP-2590972-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| WO-2015006280-A1 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-15 | — | — | WO | disclosed |
| EP-2590951-B1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2015-01-07 | — | — | EP | disclosed |
| US-8927587-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2015-01-06 | — | — | US | disclosed |
| US-20150005304-A1 | Pyran-Spirocyclic Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-01 | — | — | US | disclosed |
| US-8921306-B2 | Nociceptin mimetics | THE UNIVERSITY OF QUEENSLAND (AU) | 2014-12-30 | — | — | US | disclosed |
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| US-8916565-B2 | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140364415-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2014-12-11 | — | — | US | disclosed |
| EP-2809655-A1 | BENZIIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS SODIUM CHANNEL MODULATORS | Pfizer Inc (US) | 2014-12-10 | — | — | EP | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20140357685-A1 | Sodium Channel Inhibitors | ICAGEN INC (US) | 2014-12-04 | — | — | US | disclosed |
| WO-2014192294-A1 | POLYMORPH FORMS | RAQUALIA PHARMA INC. (JP) | 2014-12-04 | — | — | WO | disclosed |
| EP-2804868-A1 | PYRAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2593433-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-26 | — | — | EP | disclosed |
| EP-2593431-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| EP-2593428-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| EP-2590957-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-12 | — | — | EP | disclosed |
| EP-2800740-A1 | N-AMINOSULFONYL BENZAMIDES | Pfizer Limited (GB) | 2014-11-12 | — | — | EP | disclosed |
| US-20140315879-A1 | Sulfonamide Derivatives | PFIZER LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| EP-2791108-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2014-10-22 | — | — | EP | disclosed |
| EP-2593432-B1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2014-10-22 | — | — | EP | disclosed |
| US-20140309220-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-16 | — | — | US | disclosed |
| US-8853250-B2 | Sodium channel inhibitors | ICAGEN, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20140296313-A1 | (4-Phenylimidazol-2-yl) Ethylamine Derivatives Useful As Sodium Channel Modulators | PFIZER LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8846698-B2 | Pyrrolo[2,3-d]pyrimidine tropomysin-related kinase inhibitors | PFIZER LIMITED (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140275100-A1 | PYRIDAZINE DERIVATIVES USEFUL IN THERAPY | INHIBITAXIN LTD (GB) | 2014-09-18 | — | — | US | disclosed |
| EP-2175728-B1 | SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-8828996-B2 | Morpholine-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-09 | — | — | US | disclosed |
| US-8829026-B2 | Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists | RAQUALIA PHARMA INC. (JP) | 2014-09-09 | — | — | US | disclosed |
| EP-2771335-A2 | (4-PHENYLIMIDAZOL-2-YL) ETHYLAMINE DERIVATIVES USEFUL AS SODIUM CHANNEL MODULATORS | Pfizer Limited (GB) | 2014-09-03 | — | — | EP | disclosed |
| EP-2771325-A1 | PYRIDAZINE DERIVATIVES USEFUL IN THERAPY | Inhibitaxin Limited (GB) | 2014-09-03 | — | — | EP | disclosed |
| US-8809380-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20140228371-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-14 | — | — | US | disclosed |
| WO-2014120815-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014120820-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014120808-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | WO | disclosed |
| US-20140221435-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140213616-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-31 | — | — | US | disclosed |
| US-8772293-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2014-07-08 | — | — | US | disclosed |
| US-8772343-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2014-07-08 | — | — | US | disclosed |
| US-20140187583-A1 | Polymorph Form of 4-methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid | RAQUALIA PHARMA INC. (JP) | 2014-07-03 | — | — | US | disclosed |
| WO-2014104414-A1 | SALTS AND CRYSTAL FORMS | ASKAT INC. (JP) | 2014-07-03 | — | — | WO | disclosed |
| US-20140171427-A1 | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2014080633-A1 | POLYMORPH FORMS | RAQUALIA PHARMA INC. (JP) | 2014-05-30 | — | — | WO | disclosed |
| EP-2731959-A1 | ENKEPHALIN ANALOGUES | Pfizer Limited (GB) | 2014-05-21 | — | — | EP | disclosed |
| WO-2014068988-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-05-08 | — | — | WO | disclosed |
| US-20140121279-A1 | Enkephalin Analogues | PFIZER LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| WO-2014053965-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2014-04-10 | — | — | WO | disclosed |
| WO-2014053967-A1 | PYRROLO[2,3-D]PYRIMIDINE TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2014-04-10 | — | — | WO | disclosed |
| WO-2014053968-A1 | PYRROLO[3,2-C]PYRIDINE TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2014-04-10 | — | — | WO | disclosed |
| EP-2710002-A1 | POLYMORPH FORM OF 4-{[4-({[4-(2,2,2-TRIFLUOROETHOXY)-1,2-BENZISOXAZOL-3-YL]OXY}METHYL)PIPERIDIN-1-YL]METHYL}-TETRAHYDRO-2H-PYRAN-4-CARBOXYLIC ACID | RaQualia Pharma Inc (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-8653063-B2 | N-substituted saturated heterocyclic sulfone compounds with CB2 receptor agonistic activity | RAQUALIA PHARMA INC. (JP) | 2014-02-18 | — | — | US | disclosed |
| EP-2694509-A1 | PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES | Pfizer Limited (GB) | 2014-02-12 | — | — | EP | disclosed |
| WO-2014022639-A1 | SOLID FORMS OF (4-ISOPROPOXY-3-METHOXYPHENYL)(2'-METHYL-6'-(TRIFLUOROMETHYL)-3',4'-DIHYDRO-2'H-SPIRO[PIPERIDINE-4,1'-PYRROLO[1,2-A]PYRAZINE]-1-YL)METHANONE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-06 | — | — | WO | disclosed |
| EP-2686325-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2675812-A1 | CHROMAN - SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20130338111-A1 | Sulfonamide Derivatives | ICAGEN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-2670752-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2013-12-11 | — | — | EP | disclosed |
| US-8598164-B2 | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-03 | — | — | US | disclosed |
| US-8598123-B2 | Peptide analogues | PFIZER INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8592629-B2 | Sulfonamide derivatives as Nav 1.7 inhibitors | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| US-8591898-B2 | Treatment of interstitial cystitis | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| WO-2013161312-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013161308-A1 | AMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2013-10-31 | — | — | WO | disclosed |
| US-20130274243-A1 | Chemical Compounds | PFIZER LTD (GB) | 2013-10-17 | — | — | US | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| EP-2630122-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2013-08-28 | — | — | EP | disclosed |
| US-20130210858-A1 | SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2013-08-15 | — | — | US | disclosed |
| WO-2013114250-A1 | BENZIIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| WO-2013109521-A1 | PYRAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-25 | — | — | WO | disclosed |
| WO-2013102826-A1 | N-AMINOSULFONYL BENZAMIDES | PFIZER LIMITED (GB) | 2013-07-11 | — | — | WO | disclosed |
| US-8481036-B2 | Treatment of chronic prostatitis | PFIZER INC. (US) | 2013-07-09 | — | — | US | disclosed |
| WO-2013093688-A1 | SULFONAMIDE DERIVATIVES AND USE THEREOF AS VGSC INHIBITORS | PFIZER LIMITED (GB) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013088315-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| US-20130157928-A1 | NOCICEPTIN MIMETICS | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-06-20 | — | — | US | disclosed |
| US-20130150356-A1 | Acyl Piperazine Derivatives as TTX-S Blockers | RAQUALIA PHARMA INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| EP-2595989-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-2590972-A2 | CHEMICAL COMPOUNDS | Pfizer Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| EP-2590951-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | Pfizer Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| WO-2013067248-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116285-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130109667-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2013061205-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013061297-A1 | Pyridazine Derivatives Useful in Therapy | PFIZER LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| US-20130109696-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109701-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2013054185-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES USEFUL IN THERAPY | PFIZER, INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-2576598-A1 | NOCICEPTIN MIMETICS | The University of Queensland (AU) | 2013-04-10 | — | — | EP | disclosed |
| EP-2240467-B1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG | 2013-02-21 | — | — | US | disclosed |
| WO-2013008123-A1 | ENKEPHALIN ANALOGUES | PFIZER LIMITED (GB) | 2013-01-17 | — | — | WO | disclosed |
| EP-2539358-A1 | PEPTIDE ANALOGUES | Pfizer Limited (GB) | 2013-01-02 | — | — | EP | disclosed |
| US-20120329724-A1 | PEPTIDE ANALOGUES | PFIZER LIMITED | 2012-12-27 | — | — | US | disclosed |
| EP-2183241-B1 | 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LTD (GB) | 2012-12-19 | — | — | EP | disclosed |
| US-20120316150-A1 | AMIDE COMPOUNDS USEFUL IN THERAPY | PFIZER INC. | 2012-12-13 | — | — | US | disclosed |
| WO-2012157288-A1 | POLYMORPH FORM OF 4-{[4-({[4-(2,2,2-TRIFLUOROETHOXY)-1,2-BENZISOXAZOL-3-YL]OXY}METHYL)PIPERIDIN-1-YL]METHYL}-TETRAHYDRO-2H-PYRAN-4-CARBOXYLIC ACID | RAQUALIA PHARMA INC. (JP) | 2012-11-22 | — | — | WO | disclosed |
| EP-1861359-B1 | N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20120264749-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-10-18 | — | — | US | disclosed |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2012-10-11 | — | — | US | disclosed |
| WO-2012137089-A1 | PYRROLO [2, 3 -D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES | PFIZER LIMITED (GB) | 2012-10-11 | — | — | WO | disclosed |
| US-8278343-B2 | Pyrrolidines | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-09-27 | — | — | US | disclosed |
| WO-2012125613-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| WO-2012120398-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS TRPM8 MODULATORS | PFIZER LIMITED (GB) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012112743-A1 | CHROMAN - SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012106499-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-08-02 | — | — | US | disclosed |
| US-8232269-B2 | Amide compounds useful in therapy | PFIZER INC. (US) | 2012-07-31 | — | — | US | disclosed |
| WO-2012095781-A1 | INDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-07-19 | — | — | WO | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. | 2012-06-07 | — | — | US | disclosed |
| US-8178558-B2 | Substituted pyridylmethyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | US | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
| US-8163901-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2012-04-24 | — | — | US | disclosed |
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-8158650-B2 | Substituted phenylmethyl bicyclocarboxyamide compounds | PFIZER INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8153651-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2012-04-10 | — | — | US | disclosed |
| WO-2012042915-A1 | SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2012-04-05 | — | — | WO | disclosed |
| US-8138177-B2 | Benzimidazolone derivatives as CB2 receptor ligands | PFIZER INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8134007-B2 | Pyridine derivatives | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8134004-B2 | Substituted N-bicyclicalkyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2424517-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RaQualia Pharma Inc (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8124610-B2 | Sodium channel inhibitors | ICAGEN INC. (US) | 2012-02-28 | — | — | US | disclosed |
| WO-2012020567-A1 | ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-02-16 | — | — | WO | disclosed |
| EP-2215054-B8 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2012-02-08 | — | — | EP | disclosed |
| WO-2012004706-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004743-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010182-A1 | Chemical Compounds | ICAGEN INC. (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2011153583-A1 | NOCICEPTIN MIMETICS | THE UNIVERSITY OF QUEENSLAND (AU) | 2011-12-15 | — | — | WO | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| EP-1948615-B1 | Pyrazole derivatives useful for the treatment of gynaecological diseases | PFIZER LTD (GB) | 2011-12-14 | — | — | EP | disclosed |
| US-20110281840-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | ASKAT INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| EP-2385938-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011140425-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-10 | — | — | WO | disclosed |
| EP-2379533-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | RaQualia Pharma Inc (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-8044052-B2 | Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis | PFIZER INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8040476-B2 | Display device and method of producing the same | MITSUBISHI ELECTRIC CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| EP-1945630-B1 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2011-09-21 | — | — | EP | disclosed |
| WO-2011104649-A1 | PEPTIDE ANALOGUES | PFIZER LIMITED (GB) | 2011-09-01 | — | — | WO | disclosed |
| EP-2215054-B1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS INC (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20110207654-A1 | PEPTIDE ANALOGUES | PFIZER INC. | 2011-08-25 | — | — | US | disclosed |
| EP-2222631-B1 | SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2350017-A1 | AMIDE COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011077313-A1 | PIPERIDINECARBOXAMIDES AS MPGES - 1 INHIBITORS | PFIZER INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152326-A1 | SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS | HANAZAWA TAKESHI | 2011-06-23 | — | — | US | disclosed |
| US-7964732-B2 | Substituted bicyclocarboxyamide compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7960407-B2 | Crystal forms of an imidazole derivative | REQUALIA PHARMA INC. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20110130454-A1 | PRODRUGS OF GAMMA-AMINO ACID, ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2011058766-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-05-19 | — | — | WO | disclosed |
| EP-2091944-B1 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20110097341-A1 | Treatment of Chronic Prostatitis | PFIZER INC. | 2011-04-28 | — | — | US | disclosed |
| US-7915448-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2011-03-29 | — | — | US | disclosed |
| EP-2291403-A1 | TREATMENT OF CHRONIC PROSTATITIS | Pfizer Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2011018894-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | RAQUALIA PHARMA INC. (JP) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011016234-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-02-10 | — | — | WO | disclosed |
| US-20110028465-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20110021514-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2076508-B1 | BIARYL ETHER UREA COMPOUNDS | PFIZER PROD INC (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-1861377-B1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | PFIZER (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2010146511-A1 | TREATMENT OF OVERACTIVE BLADDER | PFIZER LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010137351-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010125831-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2010-11-04 | — | — | WO | disclosed |
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | Pfizer, Inc. and Renovis Inc. | 2010-10-21 | — | — | US | disclosed |
| US-20100267782-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN, INC (US) | 2010-10-21 | — | — | US | disclosed |
| EP-2240467-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100260775-A1 | Treatment Of Interstitial Cystitis | PFIZER | 2010-10-14 | — | — | US | disclosed |
| EP-1994011-B1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | RAQUALIA PHARMA INC (JP) | 2010-10-13 | — | — | EP | disclosed |
| US-20100256109-A1 | Azetidines As EP2 Antagonists | SKERRATT SARAH ELIZABETH | 2010-10-07 | — | — | US | disclosed |
| US-20100249091-A1 | Amide Compounds Useful in Therapy | GIBSON KARL RICHARD | 2010-09-30 | — | — | US | disclosed |
| EP-2231705-A2 | TREATMENT OF INTERSTITIAL CYSTITIS | Pfizer Limited (GB) | 2010-09-29 | — | — | EP | disclosed |
| US-20100240652-A1 | Pyridine Derivatives as Sodium Channel Modulators | PFIZER INC | 2010-09-23 | — | — | US | disclosed |
| US-20100227872-A1 | PYRAZINE DERIVATIVES | KEMP MARK IAN | 2010-09-09 | — | — | US | disclosed |
| EP-2222665-A1 | AZETIDINES AS EP2 ANTAGONISTS | Pfizer Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| EP-2222631-A2 | SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | Pfizer Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100216823-A1 | Spirocyclic Derivatives | PFIZER INC. | 2010-08-26 | — | — | US | disclosed |
| EP-2069302-B1 | SUBSTITUTED PYRIDYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER (US) | 2010-08-25 | — | — | EP | disclosed |
| EP-2215054-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| WO-2010084767-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| EP-1861400-B1 | CRYSTAL FORMS OF AN IMIDAZOLE DERIVATIVE | RAQUALIA PHARMA INC (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-20100120793-A1 | Pyrrolidines | PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| EP-2183241-A2 | 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | Pfizer Limited (GB) | 2010-05-12 | — | — | EP | disclosed |
| EP-2175728-A1 | SODIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2010-04-21 | — | — | EP | disclosed |
| US-7700618-B2 | Sulfonyl benzimidazole derivatives | PFIZER INC (US) | 2010-04-20 | — | — | US | disclosed |
| EP-2173743-A2 | SODIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20100087480-A1 | SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER INC. | 2010-04-08 | — | — | US | disclosed |
| WO-2010035166-A1 | BENZAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010032200-A1 | AMIDE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010029497-A1 | TREATMENT OF ENDOMETRIOSIS | PFIZER LIMITED (GB) | 2010-03-18 | — | — | WO | disclosed |
| EP-2160381-A2 | SPIROCYCLIC QUINAZOLINE DERIVATIVES AND THEIR USE AS PDE7 INHIBITORS | Pfizer Limited (GB) | 2010-03-10 | — | — | EP | disclosed |
| EP-2155666-A1 | AZETIDINE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN E2 ANTAGONISTS | Pfizer Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| EP-2155727-A1 | N-[6-AMINO-5-(PHENYL)PYRAZIN-2-YL]-ISOXAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NAV1.8 CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008142550-A9 | SPIROCYCLIC QUINAZOLINE DERIVATIVES AND THEIR USE AS PDE7 INHIBITORS | PFIZER LIMITED (GB) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7649004-B2 | Pyridine derivatives | PFIZER, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090318497-A1 | SUBSTITUTED PYRIDYLMETHYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| WO-2009150635-A1 | TREATMENT OF CHRONIC PROSTATITIS | PFIZER INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009150623-A1 | TREATMENT OF CHRONIC PROSTATITIS | PFIZER INC (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | PFIZER INC | 2009-12-03 | — | — | US | disclosed |
| US-7622589-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-2114897-A2 | BENZIMIDAZOLONE DERIVATIVES | Pfizer Products Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-7598393-B2 | Sulfonyl benzimidazole derivatives | PFIZER INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-2104503-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2009-09-30 | — | — | EP | disclosed |
| US-20090239929-A1 | N-Pyrrolidin-3-YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239928-A1 | N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1858865-B1 | SUBSTITUTED N-SULFONYLAMINOPHENYLETHYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090227562-A1 | Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor | PFIZER INC. (US) | 2009-09-10 | — | — | US | disclosed |
| EP-2091944-A2 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | Pfizer, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7576099-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7572797-B2 | Amino substituted pyrazine derivatives for the treatment of pain | PFIZER INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7566739-B2 | Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists | PFIZER INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | ANDO KAZUO | 2009-07-16 | — | — | US | disclosed |
| WO-2009089057-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INS. (US) | 2009-07-16 | — | — | WO | disclosed |
| EP-2076508-A2 | BIARYL ETHER UREA COMPOUNDS | Pfizer Products Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2009077993-A2 | TREATMENT OF INTERSTITIAL CYSTITIS | PFIZER LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
| US-20090137584-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | RAQUALIA PHARMA INC. (JP) | 2009-05-28 | — | — | US | disclosed |
| WO-2009063365-A1 | AZETIDINES AS EP2 ANTAGONISTS | PFIZER LIMITED (GB) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064449-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2005102389-A9 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090099209-A1 | Compounds Useful in Therapy | PFIZER INC | 2009-04-16 | — | — | US | disclosed |
| EP-2044018-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS | Pfizer Japan, Inc. (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-7514457-B2 | Substituted aryloxymethyl bicyclicmethyl acetamide compounds | PFIZER INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7507742-B2 | Spirocyclic derivatives | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| EP-2024272-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| US-7482375-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2009012241-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009012242-A2 | SODIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20090018158-A1 | CRYSTAL FORMS OF AN IMIDAZOLE DERIVATIVE | ASKAT INC. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20080312235-A1 | Pyridine Derivatives | LANE CHARLOTTE ALICE LOUISE | 2008-12-18 | — | — | US | disclosed |
| EP-1809607-B1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. | 2008-12-04 | — | — | US | disclosed |
| US-20080293746-A1 | COMBINATIONS COMPRISING PREGABALIN | PFIZER, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008142550-A2 | SPIROCYCLIC DERIVATIVES | PFIZER LIMITED (GB) | 2008-11-27 | — | — | WO | disclosed |
| EP-1994011-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | Pfizer, Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008139287-A1 | AZETIDINE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008135826-A2 | 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LIMITED (GB) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008135830-A1 | N- [6-AMINO-S- (PHENYL) PYRAZIN-2-YL] -ISOXAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NAV1.8 CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2008-11-13 | — | — | WO | disclosed |
| US-20080280877-A1 | Azetidines | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| WO-2008135824-A1 | OXYALKYLPYRAZOLE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008132589-A1 | COMBINATIONS COMPRISING PREGABALIN | PFIZER LIMITED (GB) | 2008-11-06 | — | — | WO | disclosed |
| EP-1984339-A1 | PYRIDINE DERIVATIVES AS SODIUM CHANNEL MODULATORS | Pfizer Limited (GB) | 2008-10-29 | — | — | EP | disclosed |
| US-20080261941-A1 | Biaryl Ether Urea Compounds | Jazz Pharmaceuticals Therapeutics, Inc. | 2008-10-23 | — | — | US | disclosed |
| US-20080261984-A1 | Use of S,S-Reboxetine in the Treatment of Pain | PFIZER INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7425569-B2 | 1H-pyrazoles useful in therapy | PFIZER INC (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080207665-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidinopropanoic Acid Compounds as Orl-1-Receptor Antagonists | PFIZER INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080200490-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| EP-1957467-A2 | SPIROCYCLIC DERIVATIVES | Pfizer Limited (GB) | 2008-08-20 | — | — | EP | disclosed |
| US-20080194841-A1 | Preparation of Optically Pure Beta-Amino Acids Having Affinity for the Alpha-Delta Protein | PFIZER INC. | 2008-08-14 | — | — | US | disclosed |
| EP-1954132-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1824837-B1 | SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008090434-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2008-07-31 | — | — | WO | disclosed |
| EP-1948615-A2 | COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008087512-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2008-07-24 | — | — | WO | disclosed |
| EP-1945630-A2 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| WO-2008059370-A2 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008050199-A2 | SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008047229-A2 | BIARYL ETHER UREA COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| US-20080096919-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096950-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080085919-A1 | 1H-Pyrazoles Useful In Therapy | BRADLEY PAUL A | 2008-04-10 | — | — | US | disclosed |
| WO-2008032164-A2 | BENZIMIDAZOLONE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1896479-A1 | ALPHA-(ARYL-OR HETEROARYL-METHYL)-BETA-PIPERIDINOPROPANOIC ACID COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | Pfizer, Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1893610-A2 | ALPHA-(ARYL-OR HETEROARYL-METHYL)-BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | Pfizer, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1893583-A1 | SUBSTITUTED ARYLOXY-N-BICYCLOMETHYL ACETAMIDE COMPOUNDS AS VR1 ANTAGONISTS | Pfizer, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2008007211-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2008-01-17 | — | — | WO | disclosed |
| EP-1874732-A1 | PYRAZOLE DERIVATIVES AS PROGESTERONE RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 2008-01-09 | — | — | EP | disclosed |
| US-7312233-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1866278-A1 | SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS | Pfizer, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| US-7309712-B2 | 1H-pyrazoles useful in therapy | PFIZER LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| EP-1863757-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1863780-A1 | PREPARATION OF OPTICALLY PURE BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | Pharmacia & Upjohn Company LLC (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1861400-A1 | CRYSTAL FORMS OF AN IMIDAZOLE DERIVATIVE | Pfizer, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1861359-A1 | N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | Pfizer, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1861377-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | Pfizer, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007135530-A2 | PHARMACEUTICALLY & VETERINARILY SUITABLE SALT | PFIZER LIMITED (GB) | 2007-11-29 | — | — | WO | disclosed |
| EP-1858865-A1 | SUBSTITUTED N-SULFONYLAMINOPHENYLETHYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER INC. (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007133637-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007129188-A1 | CYCLOPROPANECARBOXAMIDE COMPOUND | PFIZER JAPAN INC. (JP) | 2007-11-15 | — | — | WO | disclosed |
| EP-1853269-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007125398-A2 | : SULFONAMIDE COMPOUNDS AS ANTAGONISTS OF THE N-TYPE CALCIUM CHANNEL | PFIZER JAPAN INC. (JP) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007102059-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | PFIZER JAPAN INC. (JP) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007100758-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| EP-1828122-A2 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS | Pfizer Limited (GB) | 2007-09-05 | — | — | EP | disclosed |
| EP-1828121-A2 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS | Pfizer Limited (GB) | 2007-09-05 | — | — | EP | disclosed |
| EP-1828119-A1 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS | Pfizer Limited (GB) | 2007-09-05 | — | — | EP | disclosed |
| US-20070191350-A1 | Combinations comprising alpha-2-delta ligands | PIFIZER INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191462-A1 | Combination of A 5-HT(1) Receptor Agonist and an Alpha-2-Delta Ligand for the Treatment of Migraine | PFIZER LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| EP-1817281-A1 | N- [(3S)- PYRROLIDIN-3-YL]- BENZAMIDE DERIVATIVES AS MONOAMINE RE-UPTAKE INHIBITORS | Pfizer Limited (GB) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007083239-A1 | PYRIDINE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LIMITED (GB) | 2007-07-26 | — | — | WO | disclosed |
| EP-1809607-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | Pfizer, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1802580-A2 | PYRIDINE DERIVATIVES | Pfizer, Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20070129388-A1 | Phosphodiesterases inhibitors specially PDE7; To treat pain, especially neuropathic pain; superior pharmacokinetics; 3-[(8'-Chloro-2'-oxo-2',3'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'-yl)oxy]cyclobutanecarboxylic acid | PFIZER, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| WO-2007063391-A2 | SPIROCYCLIC QUINAZOLINE DERIVATIVES AS PDE7 INHIBITORS | PFIZER LIMITED (GB) | 2007-06-07 | — | — | WO | disclosed |
| EP-1791599-A1 | COMBINATION OF A 5-HT(1) RECEPTOR AGONIST AND AN ALPHA-2-DELTA LIGAND FOR THE TREATMENT OF MIGRAINE | Pfizer Limited (GB) | 2007-06-06 | — | — | EP | disclosed |
| WO-2007057775-A1 | SPIROPIPERIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007054770-A2 | PYRAZOLE DERIVATIVES AND THEIR MEDICAL USE | PFIZER LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007052123-A2 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2007-05-10 | — | — | WO | disclosed |
| US-20070105909-A1 | Compounds useful in therapy | PFIZER INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070105872-A1 | N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide | PFIZER LIMITED | 2007-05-10 | — | — | US | disclosed |
| US-7214824-B2 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1778241-A1 | COMBINATION OF A SELECTIVE NORADRENALINE REUPTAKE INHIBITOR AND A PDEV INHIBITOR | Pfizer Limited (GB) | 2007-05-02 | — | — | EP | disclosed |
| EP-1763354-A2 | USE OF REBOXETINE FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2007-03-21 | — | — | EP | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1740211-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006134485-A1 | ALPHA-(ARYL-OR HETEROARYL-METHYL)-BETA-PIPERIDINOPROPANOIC ACID COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006134486-A2 | ALPHA-(ARYL-OR HETEROARYL-METHYL)-BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006097817-A9 | N- (N-SULFONYLAMINOMETHYL) CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER JAPAN INC (JP) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006129164-A1 | SUBSTITUTED ARYLOXY-N-BICYCLOMETHYL ACETAMIDE COMPOUNDS AS VR1 ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-12-07 | — | — | WO | disclosed |
| EP-1727535-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | Pfizer Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| US-20060270682-A1 | Substituted Aryloxymethyl Bicyclicmethyl Acetamide Compounds | PFIZER, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006111856-A1 | PYRAZOLE DERIVATIVES AS PROGESTERONE RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 2006-10-26 | — | — | WO | disclosed |
| US-20060241125-A1 | Compounds useful in therapy | BRADLEY PAUL A | 2006-10-26 | — | — | US | disclosed |
| US-7122683-B2 | Amides useful as monoamine re-uptake inhibitors | PFIZER INC. (US) | 2006-10-17 | — | — | US | disclosed |
| WO-2006103503-A1 | SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006100568-A1 | PREPARATION OF OPTICALLY PURE BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006097808-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | PFIZER JAPAN INC. (JP) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097817-A1 | N- (N-SULFONYLAMINOMETHYL) CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER JAPAN INC. (JP) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006099410-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006095263-A1 | SUBSTITUTED N-SULFONYLAMINOPHENYLETHYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006095268-A1 | CRYSTAL FORMS OF AN IMIDAZOLE DERIVATIVE | PFIZER JAPAN INC. (JP) | 2006-09-14 | — | — | WO | disclosed |
| US-20060205773-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20060205980-A1 | Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists | PFIZER, INC. | 2006-09-14 | — | — | US | disclosed |
| WO-2006093832-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006092692-A1 | USE OF COMBINATIONS OF PDE7 INHIBITORS AND ALPHA-2-DELTY LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN | PFIZER LIMITED (GB) | 2006-09-08 | — | — | WO | disclosed |
| US-20060194801-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2006-08-31 | — | — | US | disclosed |
| WO-2006064332-A1 | N-PYRROLIDIN-3YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006064351-A2 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006064336-A2 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2006-06-22 | — | — | WO | disclosed |
| EP-1667957-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2006056884-A1 | N- [ (3S)- PYRROLIDIN-3-YL]- BENZAMIDE DERIVATIVES AS MONOAMINE RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006056874-A1 | SALT FORM | PFIZER LIMITED (GB) | 2006-06-01 | — | — | WO | disclosed |
| US-20060111429-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | PFIZER INC | 2006-05-25 | — | — | US | disclosed |
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006048754-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | PFIZER JAPAN INC. (JP) | 2006-05-11 | — | — | WO | disclosed |
| US-20060094750-A1 | Sulfonyl benzimidazole derivatives | KON-I KANA | 2006-05-04 | — | — | US | disclosed |
| WO-2006027681-A1 | COMBINATION OF A 5-HT(1) RECEPTOR AGONIST AND AN ALPHA-2-DELTA LIGAND FOR THE TREATMENT OF MIGRAINE | PFIZER LIMITED (GB) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006016262-A1 | COMBINATION OF A SELECTIVE NORADRENALINE REUPTAKE INHIBITOR AND A PDEV INHIBITOR | PFIZER LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006011050-A2 | PYRIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006000903-A2 | USE OF REBOXETINE FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005102390-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND NMDA RECEPTOR ANTAGONISTS | PFIZER JAPAN, INC. (JP) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005092318-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
| WO-2005030700-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030700-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016235-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, KCNJ2 | ALDH1A1 1133/4885METAP1 3630/4885GABRP 312/4885 |
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | ALDH1A1 1821/4885METAP1 3919/4885GABRP 287/4885 |
| US-20140275100-A1 | PYRIDAZINE DERIVATIVES USEFUL IN THERAPY | CYP2B6, CBR3, CYP4F3 | ALDH1A1 2014/4885METAP1 3945/4885GABRP 882/4885 |
| US-20150174127-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ5, KCNJ1 | ALDH1A1 1663/4885METAP1 3757/4885GABRP 197/4885 |
| US-20090137584-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | TRPV1, CNR2, CNR1 | ALDH1A1 3471/4885METAP1 4861/4885GABRP 307/4885 |
| US-20240238328-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | MATR3, CSGALNACT1, CD44 | ALDH1A1 1672/4885METAP1 1764/4885GABRP 2619/4885 |
| US-20170145011-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ5, KCNJ1 | ALDH1A1 1663/4885METAP1 3757/4885GABRP 197/4885 |
| US-20240294512-A1 | HYDROXY AND (HALO)ALKOXY SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | TRPV1, NHERF1, HCN4 | ALDH1A1 559/4885METAP1 4050/4885GABRP 371/4885 |
| US-20100120793-A1 | Pyrrolidines | PTGER2, PTGDR2, PTGES2 | ALDH1A1 289/4885METAP1 3243/4885GABRP 3506/4885 |
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | TRPV1, TRPA1, TRPV2 | ALDH1A1 1265/4885METAP1 3763/4885GABRP 319/4885 |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | ALDH1A1 1484/4885METAP1 1825/4885GABRP 78/4885 |
| US-20100240652-A1 | Pyridine Derivatives as Sodium Channel Modulators | TRPV1, SCN5A, TRPA1 | ALDH1A1 907/4885METAP1 3998/4885GABRP 298/4885 |
| US-10927079-B2 | Intermediate compound of novel tetrahydronaphthyl urea derivative | CCNT2, DIMT1, QTRT2 | ALDH1A1 1526/4885METAP1 2301/4885GABRP 3597/4885 |
| US-12247021-B2 | Substituted tetrahydrofurans as modulators of sodium channels | TRPV1, TRPA1, SCN2B | ALDH1A1 1562/4885METAP1 4157/4885GABRP 277/4885 |
| US-20230286961-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | TRPV1, TRPA1, SCN2B | ALDH1A1 1562/4885METAP1 4157/4885GABRP 277/4885 |
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | ALDH1A1 3784/4885METAP1 1959/4885GABRP 327/4885 |
| US-11045424-B2 | Extended release pharmaceutical formulation | CRH, HTR5A, HTR6 | ALDH1A1 1356/4885METAP1 4216/4885GABRP 637/4885 |
| US-20060205773-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | TRPV1, TRPA1, TRPV2 | ALDH1A1 1821/4885METAP1 3919/4885GABRP 287/4885 |
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN5A, SCN2A | ALDH1A1 3396/4885METAP1 3324/4885GABRP 817/4885 |
| US-20110281840-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | CNR1, CNR2, NPSR1 | ALDH1A1 3460/4885METAP1 4660/4885GABRP 314/4885 |
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | TRPV1, CNR1, CNR2 | ALDH1A1 2502/4885METAP1 4804/4885GABRP 351/4885 |
| US-20140121279-A1 | Enkephalin Analogues | OPRM1, OPRK1, OPRL1 | ALDH1A1 2602/4885METAP1 176/4885GABRP 126/4885 |
| US-20100249091-A1 | Amide Compounds Useful in Therapy | PTGER3, PTGER1, PTGER2 | ALDH1A1 1447/4885METAP1 3179/4885GABRP 2921/4885 |
| US-20220227732-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN1A, SCN2A | ALDH1A1 2945/4885METAP1 4030/4885GABRP 327/4885 |
| US-11603351-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | ALDH1A1 2665/4885METAP1 3879/4885GABRP 224/4885 |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | ALDH1A1 1369/4885METAP1 3820/4885GABRP 1381/4885 |
| US-10399945-B2 | Tetrahydronaphthyl urea derivative | OPRL1, TRPV1, TSLP | ALDH1A1 3230/4885METAP1 2181/4885GABRP 3924/4885 |
| US-12110287-B2 | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | ALDH1A1 2846/4885METAP1 4750/4885GABRP 345/4885 |
| US-12090123-B2 | Extended release pharmaceutical formulation | CRH, HTR6, HTR5A | ALDH1A1 2144/4885METAP1 4210/4885GABRP 566/4885 |
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | ALDH1A1 2024/4885METAP1 1541/4885GABRP 605/4885 |
| US-20170304277-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | GHSR, GHRHR, GIPR | ALDH1A1 2817/4885METAP1 1492/4885GABRP 183/4885 |
| US-11020381-B2 | Biaryloxy derivatives as TTX-S blockers | SCN1B, SCN3A, SCN2B | ALDH1A1 2091/4885METAP1 3294/4885GABRP 195/4885 |
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | ALDH1A1 643/4885METAP1 4088/4885GABRP 1633/4885 |
| US-20150105393-A1 | AMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN5A, SCN1A | ALDH1A1 2669/4885METAP1 3627/4885GABRP 280/4885 |
| US-20100227872-A1 | PYRAZINE DERIVATIVES | CYP3A5, TRPV5, TRPV1 | ALDH1A1 617/4885METAP1 3448/4885GABRP 1908/4885 |
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN8A, SCN1B, SCN3A | ALDH1A1 2279/4885METAP1 3501/4885GABRP 682/4885 |
| US-12258333-B2 | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN2B | ALDH1A1 1741/4885METAP1 3728/4885GABRP 233/4885 |
| US-11834441-B2 | Substituted tetrahydrofurans as modulators of sodium channels | TRPV1, TRPA1, SCN2B | ALDH1A1 1562/4885METAP1 4157/4885GABRP 277/4885 |
| US-20150094306-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | SCN5A, SCN1B, SCN1A | ALDH1A1 2675/4885METAP1 2917/4885GABRP 168/4885 |
| US-11471415-B2 | Extended release pharmaceutical formulation and methods of treatment | CRH, HTR5A, NPY5R | ALDH1A1 2863/4885METAP1 4349/4885GABRP 350/4885 |
| US-20240018103-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | ALDH1A1 4326/4885METAP1 2816/4885GABRP 532/4885 |
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | ALDH1A1 2581/4885METAP1 4637/4885GABRP 349/4885 |
| US-10253054-B2 | Prodrugs of pyridone amides useful as modulators of sodium channels | TRPV1, P2RY1, P2RX3 | ALDH1A1 886/4885METAP1 4031/4885GABRP 896/4885 |
| US-12552776-B2 | Crystalline forms | MLNR, SIGMAR1, PROKR1 | ALDH1A1 2850/4885METAP1 140/4885GABRP 678/4885 |
| US-20190262386-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | CSGALNACT1, MATR3, CD44 | ALDH1A1 1763/4885METAP1 1348/4885GABRP 2219/4885 |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | ALDH1A1 1762/4885METAP1 3273/4885GABRP 192/4885 |
| US-20150246028-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, KCNJ2 | ALDH1A1 1133/4885METAP1 3630/4885GABRP 312/4885 |
| US-20100087480-A1 | SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | TRPV1, P2RY1, TRPV2 | ALDH1A1 950/4885METAP1 2444/4885GABRP 141/4885 |
| US-12350378-B2 | Extended release pharmaceutical formulation and methods of treatment | CRH, HTR5A, NPY5R | ALDH1A1 2863/4885METAP1 4349/4885GABRP 350/4885 |
| US-20160376295-A1 | PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS | TRPV1, P2RY1, P2RX3 | ALDH1A1 886/4885METAP1 4031/4885GABRP 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.